Pliant Therapeutics, Inc. (PLRX): Capital Expenditures
$374.0K
Year ended 2025-12-31
$0
Trailing 12 months to 2026-06-30
-40.3%
3-year compound annual growth
-24.6%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $374.0K | -90.3% | 2026-03-11, From 2025-01-01 |
| 2024-12-31 | $3.85M | +317.8% | 2026-03-11, From 2024-01-01 |
| 2023-12-31 | $921.0K | -47.7% | 2025-03-03, From 2023-01-01 |
| 2022-12-31 | $1.76M | -9.9% | 2025-03-03, From 2022-01-01 |
| 2021-12-31 | $1.95M | +27.5% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $1.53M | +58.9% | 2022-03-01, From 2020-01-01 |
| 2019-12-31 | $964.0K | n/a | 2022-03-01, From 2019-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Pliant Therapeutics, Inc. (PLRX) | 2025-12-31 | $374.0K | -90.3% |
| Abbott Laboratories (ABT) | 2025-12-31 | $2.17B | -1.6% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $1.31B | +5.0% |
| Pfizer Inc (PFE) | 2025-12-31 | $2.63B | -9.6% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $4.83B | +9.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $6.48M | -40.9% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $4.11B | +21.9% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $28.0K | n/a |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $317.0K | -81.4% |
Compare PLRX, ABT, BMY, PFE side by side · Screen every company in Pharmaceutical Preparations ↗